Takeda Announces New Assignments of Directors

June 24, 2020

Osaka, Japan, June 24, 2020 --- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced new assignment of Directors. The details are as follows;

New assignment of Non-Audit and Supervisory Committee Directors effective June 24, 2020;

Name	Category		Role
Christophe Weber	Internal	Existing	Representative Director, President & Chief Executive Officer
Masato Iwasaki	Internal	Existing	Director, President, Japan Pharma Business Unit
Andrew Plump	Internal	Existing	Director, President, Research & Development
Constantine Saroukos	Internal	Existing	Director, Chief Financial Officer
Masahiro Sakane	External	Existing	External Director, Chair of the Board Meeting
Olivier Bohuon	External	Existing	External Director
Jean-Luc Butel	External	Existing	External Director
Ian Clark	External	Existing	External Director
Yoshiaki Fujimori	External	Existing	External Director
Steven Gillis	External	Existing	External Director
Shiro Kuniya	External	Existing	External Director
Toshiyuki Shiga	External	Existing	External Director

New assignment of Audit and Supervisory Committee Directors effective June 24, 2020;

Name	Category		Role
Yasuhiko Yamanaka	Internal	Existing	Director, Full-time Audit & Supervisory Committee member
Koji Hatsukawa	External	Existing	External Director, Chairperson of Audit & Supervisory Committee
Emiko Higashi	External	Existing	External Director, Audit & Supervisory Committee member
Michel Orsinger	External	Existing	External Director, Audit & Supervisory Committee member

New assignment of Compensation committee and Nomination committee effective June 24, 2020;

Compensation committee : Emiko Higashi (Chair), Olivier Bohuon, Ian Clark, Yoshiaki Fujimori
Nomination committee : Masahiro Sakane (Chair), Jean-Luc Butel, Steven Gillis,
Toshiyuki Shiga, Michel Orsinger, Christophe Weber (Observer)

Media Contact:

Kazumi Kobayashi
[email protected]
+81 (0) 3-3278-2095